Cannvas MedTech (CSE:MTEC) , a leading digital cannabis educator and business technology company, is pleased to announce the first appointee to its newly-formed Cannabis Sciences Advisory Board, providing independent scientific oversight and original content for the Cannvas.Me cannabis education platform. Angela Smith, PhD, joins Cannvas as the Board lead, bringing with her a wealth of experience in medical, scientific and clinical affairs for Canadian medicinal and recreational cannabis brands and natural health products, and leading international food brands.
“We are thrilled to welcome Angela to the Cannvas team as the first member of our Cannabis Sciences Advisory Board, where she will be instrumental in guiding our educational content to better disseminate timely evidence-based scientific research around cannabis and its myriad uses,” said Shawn Moniz, Chief Executive Officer, Cannvas MedTech Inc. “Cannvas continues to lead the way in accessible and physician-backed, educator-approved cannabis education, and Angela’s appointment strengthens our commitment to go above and beyond basic Cannabis 101 and provide users with credible knowledge and justification around the latest studies on cannabis and their impact on the health and wellness of Canadians.”
The Cannabis Sciences Advisory Board is an independent panel of esteemed and established scientific consultants from across a range of industries providing oversight and original content to the Cannvas.Me digital cannabis education platform. As the first appointee, Angela will lead the Board’s activities in determining in which areas of current cannabis scientific research to focus its efforts while leveraging her past experience coordinating and managing medical expert advisory boards to develop the structure of the Board’s contributions, activities and inquiries.
A PhD-level scientist with over a decade of experience in basic and clinical research and teaching, and expert knowledge in regulatory, medical, scientific, and technical affairs, Angela is the founder of Catalyst Life Sciences Consulting, a boutique firm providing a wide range of medical, scientific and regulatory consulting services for Canadian natural health products, highly regulated food products including infant formulas and foods, and medical and recreational cannabis. She brings with her a strong working knowledge of North American and international regulatory frameworks, including the Federal Cannabis Act and Provincial/Territorial cannabis regulatory frameworks.
Angela spent 10 years in the food and natural health products industry, leading and supporting prenatal, maternal and infant scientific affairs. Her expertise included the preparation of evidence-based regulatory documentation and scientific evidence, coordination, development and evaluation of educational program initiatives for healthcare professionals and consumers, and providing scientific expertise and evidence-based guidance to senior executives.
Angela has worked on projects with the University of Toronto, Toronto’s Hospital for Sick Children and B.C. Women’s and Children’s Hospital, among others. Angela has amassed a great deal of experience developing and managing medical and continuing education programs for healthcare professionals through organizations including the College of Family Physicians of Canada, the Royal College of Physicians and Surgeons of Canada and the Canadian Council on Continuing Education in Pharmacy. Over her career she has also made valuable contributions to stakeholder consultations on health policies and position statements with the federal government, expert groups and associations.
Operating independent of any licenced producers or clinics, Cannvas.Me works with its Medical Advisory Board and Educational Advisory Panel and newly-formed Cannabis Sciences Advisory Board to provide a safe space for cannabis education with no pressure to purchase or consume.
The Cannabis Sciences Advisory Board will consist of prominent Canadians and Americans who are among the leaders in their fields with robust backgrounds in education, health sciences, medicine and research. Members of the Board will be in constant communication with the Cannvas.Me team to offer guidance on new educational modules, oversight of and contributions to original Cannvas.Me content, and insights into health sciences, clinical trials, medical, scientific and regulatory affairs, and other related topics.
Additionally, the company issued a total of 487,500 common shares (the “Shares”) at a deemed value of $0.30 per share to certain persons and a related party for fees owed totaling approximately $146,250.
About Cannvas MedTech Inc.
Cannvas MedTech is a leading digital cannabis education and business technology company within the health sciences space. We design and build patient-centric platforms that enable our partners to harness the power of data to truly understand their customers.
For additional information:
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.
For further information: Investor Relations: Renmark Financial Communications Inc., Shushu Feng: email@example.com, Tel: (416) 644-2020 or (212) 812-7680
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).